UCL School of Pharmacy, University College London, UK.
UCL Institute of Ophthalmology, University College London, UK.
Biochim Biophys Acta Mol Basis Dis. 2020 Sep 1;1866(9):165772. doi: 10.1016/j.bbadis.2020.165772. Epub 2020 Mar 24.
The neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease, are a group of rare monogenic neurodegenerative diseases predominantly affecting children. All NCLs are lethal and incurable and only one has an approved treatment available. To date, 13 NCL subtypes (CLN1-8, CLN10-14) have been identified, based on the particular disease-causing defective gene. The exact functions of NCL proteins and the pathological mechanisms underlying the diseases are still unclear. However, gene therapy has emerged as an attractive therapeutic strategy for this group of conditions. Here we provide a short review discussing updates on the current gene therapy studies for the NCLs.
神经元蜡样脂褐质沉积症(NCLs),又称 Batten 病,是一组主要影响儿童的罕见单基因神经退行性疾病。所有 NCL 都是致命且无法治愈的,只有一种已获得批准的治疗方法。迄今为止,已经根据特定的致病缺陷基因确定了 13 种 NCL 亚型(CLN1-8、CLN10-14)。NCL 蛋白的确切功能和疾病的病理机制尚不清楚。然而,基因治疗已成为治疗这类疾病的一种有吸引力的治疗策略。在这里,我们提供了一篇简短的综述,讨论了 NCL 基因治疗研究的最新进展。